Role of Kankasav in the management of spo2 level of covid 19 patients

ROLE OF KANAKASAV IN THE MANAGEMENT OF COVID-19 PATIENT WITH SPECIAL REFERENCE TO ARTERIAL BLOOD OXYGEN LEVEL (SpO2)-PROSPECTIVE OPEN LABELLED MULTICENTRIC CLINICAL STUDY

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/05/033695

Enrollment

Registered

2021-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Kankasav: This is ayurvedic formulation given 15 ml thrice a day for 5 days Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with positive rapid antigen test OR RT-PCR â?? reverse transcription polymerase chain reaction with blood oxygen saturation (SpO2) >= 85 up to 94 HRCT score >=7 or above Subjects having at least any one of the diagnostic criteria. Patient between age group 20-70 years of age. Patients of any gender, and willing for trial. Irrespective of socioeconomic condition of patient.

Exclusion criteria

Exclusion criteria: 1) Subjects having critical illness. 2) subjects having SPo2 below 85. 3) Subjects not willing for trial. 4) Pregnant females and lactating mothers.

Design outcomes

Primary

Measure	Time frame
SPo2 level of patients are increased and dyspnoea reducedTimepoint: 2 to 3 weeks	—

Secondary

Measure	Time frame
Changes in pulse rate,respiratory rate,Timepoint: 2 to 3 weeks	—

Countries

India

Contacts

Public ContactDrAbhijit Ahire

Govt Ayurved Hospital Nanded

abhijitahire@gmail.com7774048512

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026